Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Herman Waldmann Jeanette Lundin Peppy Rebello Geoff Hale |
| Publication date | August 1, 2002 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |